Accessibility Menu
OmniAb logo

OmniAb(NASDAQ) OABI

Market Cap$287.05MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-78%
5 YearN/A
1 Year+4%
1 Month-17%
$1.99
+0.00%
+0.00Today
After hours$1.99+$0.00 (+0.00%)
OmniAb last closing stock price
MetricPriceDate
Last closeUSD 1.982026-07-31
OmniAb stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.46%USD 2.032026-07-24
1 month-17.15%USD 2.392026-07-01
3 month+41.43%USD 1.402026-05-01
Year to date+7.03%USD 1.852025-12-31
1 year+3.66%USD 1.912025-07-31
3 year-64.26%USD 5.542023-08-01
Since inception-77.74%USD 8.942022-10-25

OmniAb Financials at a Glance

Market Cap

$287.05MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$28.91M

Net Income (TTM)

-$54.28M

EPS (TTM)

-$0.46

P/E Ratio

-4.26

Dividend

$0.00

Beta (Volatility)

1.75 (High)

Price

$1.99

Volume

275,282.068

Open

$1.99

Previous Close

$1.98

Daily Range

$1.90 - $2.04

52-Week Range

$1.30 - $2.79

Estimated Earnings Date

Aug 6, 2026

OABI News

No articles available.

OABI: Motley Fool Moneyball Superscore

46

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About OmniAb

OmniAb helps drug companies find new medicines using special animals. This technology makes it easier to create treatments for various diseases. Many pharmaceutical firms pay to use these tools for their research.

Tools for Making Medicines

  • Transgenic Animals: Genetically modified rats, chickens, and mice that produce human-like antibodies for medical research.
  • Bispecific Applications: Specialized platforms like OmniFlic and OmniClic that help partners develop drugs designed to hit two targets at once.
  • Complex Target Discovery: Technologies like OmniTaur use the unique traits of cow antibodies to find treatments for difficult diseases.
  • Ion Channel Research: Specialized tools focused on proteins that control the flow of ions across cell membranes.

Recent Moves and Partnerships

  • Completed a $30 million private investment in August 2025 to support ongoing operations.
  • Entered into a sales agreement with Jefferies LLC in December 2023 to potentially raise up to $100 million through stock sales.
  • Consummated a business combination with Avista Public Acquisition Corp. II in November 2022 to become a public company.
  • Discontinued certain legacy small molecule ion channel programs during the first quarter of 2026.

What Sets OmniAb Apart?

The company maintains a diverse fleet of engineered animals to generate antibody repertoires that mirror human immune responses. This biological approach combines with artificial intelligence and high-speed screening to accelerate drug discovery for 107 active partners.

A Look at the Numbers

  • Total revenue rose to $14.4 million in Q1 2026, up 246.7% from $4.2 million in Q1 2025.
  • Net loss reached $7.7 million in Q1 2026, an improvement of 57.7% from the previous year.
  • Free cash flow was negative $5.1 million in Q1 2026, an improvement of 68.4% from Q1 2025.
  • The company held $49.1 million in cash and short-term investments as of March 31, 2026.

The Big Picture

OmniAb has transitioned from a specialized research unit into a public platform supporting hundreds of active drug development programs. Its evolution toward a royalty-based business model depends on the long-term clinical success of its pharmaceutical partners.

AI Generated • May 13, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

89

CEO

Matthew William Foehr

Website

www.omniab.com

Headquarters

EmeryVille, CA 94608, US

OABI Financials

Key Financial Metrics (TTM)

Gross Margin

35.45%

Operating Margin

-200.35%

Net Income Margin

-187.74%

Return on Equity

-20.31%

Return on Capital

-24.89%

Return on Assets

-18.48%

Earnings Yield

-23.47%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$287.05MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

144.97M

Volume

275.28K

Avg. Volume

685.50K

Financials (TTM)

Gross Profit

$10.25M

Operating Income

-$57.93M

EBITDA

-$33.82M

Operating Cash Flow

-$25.50M

Capital Expenditure

-$523.00K

Free Cash Flow

-$26.02M

Cash & ST Invst.

$49.07M

Total Debt

$19.67M

OmniAb Performance Analysis

OmniAb annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 59,077,00070.0%
20232023-12-31USD 34,164,000-42.2%
20242024-12-31USD 26,391,000-22.8%
20252025-12-31USD 18,666,000-29.3%
OmniAb sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-6.2%
Q32025-09-30-42.5%
Q42025-12-31274.1%
Q12026-03-3171.9%
OmniAb annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.26-20.0%
20232023-12-31USD -0.5194.0%
20242024-12-31USD -0.6119.3%
20252025-12-31USD -0.57-5.9%
OmniAb sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3011.8%
Q32025-09-306.7%
Q42025-12-3121.4%
Q12026-03-3145.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$14.40M

+246.7%

Gross Profit

$8.40M

+102.2%

Gross Margin

58.33%

N/A

Market Cap

$287.05MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.23M

N/A

Employees

89

N/A

Net Income

-$7.70M

+57.7%

EBITDA

-$1.70M

+87.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$49.07M

+12.6%

Total Debt

$19.67M

-12.5%

Accounts Receivable

$12.64M

+95.1%

Inventory

$0.00

N/A

Long Term Debt

$15.73M

-15.7%

Short Term Debt

$3.94M

+3.3%

Return on Assets

-18.48%

N/A

Return on Invested Capital

-20.68%

N/A

Free Cash Flow

-$5.08M

+68.4%

Operating Cash Flow

-$4.91M

+69.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TARAProtara Therapeutics, Inc.
$3.92-2.73%
CCCCC4 Therapeutics, Inc.
$3.48-4.92%
IPHAInnate Pharma S.A.
$1.75+0.29%
IVVDInvivyd, Inc.
$0.54-8.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About OABI

What is the current price of OmniAb?

OmniAb is trading at $1.98 per share.

What is the 52-week range for OmniAb?

Over the past 52 weeks, OmniAb has traded between $1.30 and $2.79.

How much debt does OmniAb have?

As of the most recent reporting period, OmniAb reported total debt of $19.67M.

How much cash does OmniAb have on hand?

OmniAb reported $29.05M in cash and cash equivalents in its most recent financial results.

What is OmniAb’s dividend yield?

OmniAb does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services